VExUS Combined With CVP to Predict Clinical Outcomes in Sepsis Participants
Introduction: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection, and it is a common critical condition in the ICU. Early and timely fluid resuscitation is the cornerstone of sepsis treatment. However, excessive fluid loading can lead to interstitial edema and iatr
| Condition(s) | Sepsis, Acute Kidney Injury |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Introduction: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection, and it is a common critical condition in the ICU. Early and timely fluid resuscitation is the cornerstone of sepsis treatment. However, excessive fluid loading can lead to interstitial edema and iatrogenic organ damage, particularly acute kidney injury (AKI). The VExUS grading system is a recently developed system that measures venous congestion through bedside ultrasound by assessing the blood flow waveforms of the portal vein, hepatic vein, and intrarenal veins, as well as the diameter of the inferior vena cava. Similarly, CVP is a commonly used indicator of venous congestion. The objective of this study is to Investigate the association between Venous Excess Ultrasoun |
| Who can participate | Inclusion Criteria: * Adult participants (age ≥ 18 years) with sepsis upon admission or during their stay in the ICU. Exclusion Criteria: * Age \< 18 years * Participants admitted to the ICU for \< 24 hours * Pregnant or lactating women * Severe renal impairment (defined as baseline estimated glomerular filtration rate \< 15 mL/min or requiring regular dialysis), including causes such as urinary tract obstruction, contrast agents, or nephrotoxic drugs * Liver cirrhosis with portal hypertension * Presence of urinary tract obstruction (which may affect IRVF waveform) * Inability to resolve the primary disease * Participants receiving palliative care * Inability to obtain ultrasound images * Inability to monitor CVP * Refusal of monitoring by participants or their families |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Lead sponsor | The Second People's Hospital of Yibin |
| Locations | Yibin, Sichuan, China |
| Start date | 2024-07-01 |
| NCT ID | NCT06524622 |
| Official listing | https://clinicaltrials.gov/study/NCT06524622 |